InnovAge Holding Corp. — FY2022 Form 10-K
Reporting period: Fiscal year ended June 30, 2022; the filing reports annual results, not standalone fourth-quarter results. InnovAge operates a single reportable PACE business, providing fully capitated care to frail, predominantly dual-eligible seniors. At year-end, it served approximately 6,650 participants through 18 centers in five states.
Financial and operating performance
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $698.6 million | $637.8 million | +9.5% |
| Operating income (loss) | $(4.4) million | $(12.3) million | Loss narrowed |
| Net income (loss) | $(8.0) million | $(44.7) million | Loss narrowed |
| Net loss attributable to InnovAge | $(6.5) million | $(44.0) million | Loss narrowed |
| Operating cash flow | $27.3 million | $(7.5) million | Improved by $34.9 million |
| Cash and cash equivalents at year-end | $184.4 million | $201.5 million | Down $17.1 million |
| Total debt principal | $73.6 million | $77.4 million | Down $3.8 million |
- Capitation revenue was $697.0 million, up 9.7%; it represented nearly all revenue. Growth reflected higher Medicare and Medicaid rates and a 4.3% rise in total member months.
- Year-end census was approximately 6,650, down from 6,850. Total member months rose to 82,820 from 79,430, reflecting enrollment during the year despite lower year-end census.
- External provider costs increased 23.8% to $383.0 million, faster than revenue, while cost of care excluding depreciation and amortization increased 16.7% to $180.2 million. Management cited higher utilization and costs, including COVID-19-related inpatient care, post-acute and housing costs, delayed care, reopening centers, wage pressure, and audit remediation.
- Operating margin was approximately -0.6% versus -1.9%. Net loss margin improved to approximately -1.1% from -7.0%. Adjusted EBITDA, a non-GAAP measure, fell 59.9% to $34.3 million; its margin declined to 4.9% from 13.4%.
- Cash used in investing was $40.2 million, mainly for property and equipment and an integrated electronic medical record system. Cash used in financing was $6.3 million. Cash, cash equivalents and restricted cash decreased $19.3 million.
- Current assets were $241.0 million and current liabilities $105.3 million at year-end. Debt included $71.3 million under the term loan and $2.3 million under a convertible term loan. The $100 million revolving facility had no borrowings outstanding, subject to covenants and borrowing conditions. The term loan rate was 3.83% at June 30, 2022; the company reported covenant compliance.
Material changes and unusual items
- Net loss improved substantially year over year, in part because FY2021 included $45.4 million of expense related to cancellation of equity awards, $13.1 million of Apax transaction costs, $18.2 million of contingent consideration expense, a $14.5 million debt extinguishment loss, and a $10.9 million gain on consolidation of an equity-method investment. These items make year-over-year comparisons less representative of recurring performance.
- FY2022 Center-level Contribution Margin declined to $135.4 million from $174.1 million; as a percentage of revenue, it fell to 19.4% from 27.3%.
- The company restated its June 30, 2021 balance-sheet and equity presentation to classify $17.0 million of redeemable noncontrolling interests as temporary rather than permanent equity. Management concluded the prior-period error was not material.
- Management reported no goodwill impairment, despite conducting interim assessments following regulatory and growth restrictions.
Outlook, risks and contingencies
- No specific FY2023 revenue, earnings, enrollment or margin guidance is provided. Management expects expenses to increase in absolute dollars, including from compliance, audit remediation, legal matters, public-company costs, staffing, and technology investment. Growth depends in part on resolving regulatory restrictions.
- CMS and state regulators suspended new enrollments at the Sacramento center and all Colorado centers following audit deficiencies involving care delivery, coordination and documentation. Corrective action plans were accepted and monitoring or validation was ongoing; lifting the sanctions remained uncertain. Audits in Albuquerque and San Bernardino identified deficiencies, with the company reporting that regulators verbally indicated no enforcement actions would be taken, while close-out work remained underway.
- Growth plans were also constrained: Kentucky said it would not enter a PACE agreement, CMS denied the Terre Haute, Indiana center application, and the company paused remaining steps for planned Florida centers. California’s state assurances for new centers were suspended pending remediation and validation in Sacramento.
- The company faces Colorado and DOJ civil investigative demands under false-claims laws, a putative securities class action alleging misleading statements and omissions, and a shareholder books-and-records demand concerning alleged governance issues. Outcomes and potential financial effects were not predictable from the filing.
- Material business risks include full responsibility for participant care costs under fixed capitation rates; dependence on Medicare, Medicaid and a few states; risk-adjustment payment audits and potential repayments; labor shortages, wage and inflation pressure; and extensive healthcare regulation. Colorado, California and Virginia together accounted for approximately 83.3% of capitation revenue.
- Management said cash, operating cash flows and available financing were expected to fund operating and capital needs for the next 12 months and beyond, but noted that estimates depend on assumptions. The filing also describes variable-rate debt, restrictive credit covenants and potential future capital needs.
- The independent auditor gave an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.
Investor verification priorities
- Track whether CMS and state agencies accept remediation and lift enrollment sanctions, and confirm the timing and conditions for reopening growth opportunities.
- Review developments and potential exposure in the Colorado and DOJ investigations, securities litigation, and shareholder demand.
- Monitor participant census, member months, capitation rate updates and risk-score true-ups, alongside medical-cost growth and Center-level Contribution Margin.
- Reconcile adjusted EBITDA and its exclusions to GAAP results; assess whether the year-over-year loss improvement reflects recurring operations or prior-year unusual charges.
- Check operating cash generation, capital spending, debt service, covenant compliance and liquidity as remediation and compliance costs continue.